查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
普伐他汀市場 2022-2028
市場調查報告書
商品編碼
1215663

普伐他汀市場 2022-2028

Pravastatin Market 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 | 商品交期: 2-3個工作天內

價格

在預測期內，普伐他汀的全球市場預計將以 5.4% 的複合年增長率增長。 不斷增加的藥物研究活動正在為市場創造發展機會。 例如，2021 年 7 月，一項從 2020 年 1 月到 2020 年 9 月的全美國醫院範圍的研究將表明，他汀類藥物可降低既往患有高血壓和心髒病的 COVID-19 患者的死亡風險。我是。 該研究包括 104 家美國醫院的大約 10,500 名患者。 所有人都因 COVID-19 重病住院。 美國心臟協會對數據的分析得出結論，他汀類藥物的使用同樣可以將 COVID-19 感染導致嚴重後果的風險降低 25%。 普伐他汀可降低血液中的低密度脂蛋白（壞）膽固醇和甘油三酯，並增加高密度脂蛋白（好）膽固醇。 它僅作為仿製藥銷售，沒有品牌藥。 它也僅以平板電腦形式出售。 該報告進一步打算分析在預測期內直接或間接影響普伐他汀市場增長的所有主要和次要因素。

全球普伐他汀市場根據劑量類型和最終用戶進行細分。 根據劑量類型，市場分為 10 毫克片劑、20 毫克片劑、40 毫克片劑和 80 毫克片劑。 基於最終用戶，市場分為兒科和成人。 這些部分可以根據要求的研究要求進一步定制。

從地域上看，全球普伐他汀市場分為北美、歐洲、亞太地區和世界其他地區。 我們還可以應要求提供特定地區或國家層面的市場分析。 歐洲在普伐他汀的全球市場中佔有很大份額。 推動歐洲市場增長的因素包括心血管疾病患病率上升。 根據 2017 年歐洲心血管疾病統計，歐洲每年有 390 萬人死於心血管疾病，歐盟夥伴國家每年有 180 萬人死於心血管疾病。 這分別佔歐洲和歐盟登記死亡人數的 45% 和 37%。 因此，日益加重的心血管疾病負擔將增加該地區對普伐他汀醫藥產品的需求。

內容

第 1 章報告概述

  • 當前行業分析和增長前景
  • COVID-19 對全球普伐他汀市場的影響
  • 全球普伐他汀市場的複蘇情景
  • 研究方法和工具
  • 市場細分
    • 按細分
    • 按地區

第 2 章市場概述和洞察

  • 調查範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 推薦
    • 總結

第三章競爭格局

  • 主要公司分析
    • 百時美施貴寶公司
    • 諾華國際公司
    • Glenmark Pharmaceuticals Ltd.
    • 雷迪博士實驗室有限公司
  • 關鍵策略分析
  • COVID-19 對主要參與者的影響

第四章市場細分

  • 全球普伐他汀市場：按劑量類型分類
    • 10 毫克片劑
    • 20 毫克片劑
    • 40 毫克片劑
    • 80 毫克片劑
  • 全球普伐他汀市場：按最終用戶分類
    • 兒科
    • 成人

第五章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他亞太地區
  • 世界其他地方

第六章公司簡介

  • Accord Healthcare, Ltd.
  • Apotex, Inc.
  • Aurobindo Pharma Ltd.
  • Cipla, Inc.
  • Daiichi Sankyo Co
  • Jiangxi Boyaseehot Pharmaceutical Co., Ltd.
  • Lupin Ltd.
  • Mylan N.V.
  • North China Pharmaceutical Group
  • Shanghai Shyndec Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Upsher-Smith Laboratories, LLC
  • Zhejiang Hisun Pharmaceutical Co., Ltd.
  • Zydus Pharmaceuticals, Inc.
Product Code: OMR2026719

Title:Global Pravastatin Market Size, Share, and Trends Analysis Report, by Dosage Type (10 mg Tablet, 20 mg Tablet, 40 mg Tablet, and 80 mg Tablet) and by End User (Children and Adults), Forecast Period (2022-2028).

The global pravastatin market is anticipated to grow at a CAGR of 5.4% during the forecast period. The rising pharmaceutical research activities are generating development opportunities for the market. For instance, in July 2021, a study was conducted across the US hospitals between January and September 2020 to show that the Statins reduce the risk of mortality in COVID-19 patients with a history of high blood pressure or heart disease. The study was conducted on around 10,500 patients across 104 US hospitals. All of them had been admitted with a serious COVID-19 disease. After analyzing the data by American Heart Association, it was concluded that statin use was similarly linked to a 25% lower risk for developing a severe outcome as a result of COVID-19 infection. Pravastatin reduces LDL (bad) cholesterol and triglycerides in the blood and increases HDL (good) cholesterol. It is only available as a generic drug and it doesn't have a brand name version. It comes only in the form of a tablet. This report will further analyze all the primary as well as secondary factors that are directly or indirectly influencing the growth of the pravastatin market during the forecast period.

The global pravastatin market is segmented based on dosage type and end-users. Based on the dosage type, the market is segmented into 10 mg tablets, 20 mg tablets, 40 mg tablets, and 80 mg tablets. Based on the end-users, the market is sub-segmented into children and adults. These segments can further be customized as per the requested research requirements.

Geographically, the global pravastatin market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The market can also be analyzed for a particular region or country level as per the requirement. Europe holds a considerable share in the global pravastatin market. The factors driving the European market growth include the rising prevalence of cardiovascular disorders. According to the European Cardiovascular Disease Statistics 2017, there were 3.9 million fatalities reported due to cardiovascular diseases every year in Europe, while 1.8 million deaths were reported in the EU partner nations every year. This represents 45% and 37% of the total fatalities registered across the Europe and EU respectively. Thus, the rising burden of cardiovascular disease will increase the demand for pravastatin drugs in this region.

The major companies serving the global pravastatin market include Bristol-Myers Squibb, Novartis International AG, Glenmark Pharmaceuticals Ltd., Dr. Reddy's Laboratories, Cipla Inc., Lupin Ltd., Aurobindo Pharma Ltd., and Teva Pharmaceutical Industries Ltd., among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market.

Research Methodology

The market study of the global pravastatin market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of the market size, and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Pravastatin Market Research and Analysis by Dosage Type.
  • Global Pravastatin Market Research and Analysis by End User.

The Report Covers:

  • Comprehensive research methodology of the global pravastatin market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global pravastatin market.
  • Insights about market determinants that are stimulating the global pravastatin market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Pravastatin Market
  • Recovery Scenario of Global Pravastatin Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Bristol-Myers Squibb, Co.
      • 3.1.1.1. Overview
      • 3.1.1.2. Financial Analysis
      • 3.1.1.3. SWOT Analysis
      • 3.1.1.4. Recent Developments
    • 3.1.2. Novartis International AG
      • 3.1.2.1. Overview
      • 3.1.2.2. Financial Analysis
      • 3.1.2.3. SWOT Analysis
      • 3.1.2.4. Recent Developments
    • 3.1.3. Glenmark Pharmaceuticals Ltd.
      • 3.1.3.1. Overview
      • 3.1.3.2. Financial Analysis
      • 3.1.3.3. SWOT Analysis
      • 3.1.3.4. Recent Developments
    • 3.1.4. Dr. Reddy's Laboratories, Ltd.
      • 3.1.4.1. Overview
      • 3.1.4.2. Financial Analysis
      • 3.1.4.3. SWOT Analysis
      • 3.1.4.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on Key Players

4. Market Segmentation

  • 4.1. Global Pravastatin Market by Dosage Type
    • 4.1.1. 10 mg Tablet
    • 4.1.2. 20 mg Tablet
    • 4.1.3. 40 mg Tablet
    • 4.1.4. 80 mg Tablet
  • 4.2. Global Pravastatin Market by End User
    • 4.2.1. Children
    • 4.2.2. Adults

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. US
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Accord Healthcare, Ltd.
  • 6.2. Apotex, Inc.
  • 6.3. Aurobindo Pharma Ltd.
  • 6.4. Cipla, Inc.
  • 6.5. Daiichi Sankyo Co
  • 6.6. Jiangxi Boyaseehot Pharmaceutical Co., Ltd.
  • 6.7. Lupin Ltd.
  • 6.8. Mylan N.V.
  • 6.9. North China Pharmaceutical Group
  • 6.10. Shanghai Shyndec Pharmaceutical Co. Ltd.
  • 6.11. Teva Pharmaceutical Industries Ltd.
  • 6.12. Upsher-Smith Laboratories, LLC
  • 6.13. Zhejiang Hisun Pharmaceutical Co., Ltd.
  • 6.14. Zydus Pharmaceuticals, Inc.

LIST OF TABLES

  • 1. GLOBAL PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL 10 MG PRAVASTATIN TABLETS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL 20 MG PRAVASTATIN TABLETS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL 40 MG PRAVASTATIN TABLETS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL 80 MG PRAVASTATIN TABLETS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY END USER, 2021-2028 ($ MILLION)
  • 7. GLOBAL PRAVASTATIN FOR CHILDREN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL PRAVASTATIN FOR ADULTS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. NORTH AMERICAN PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 11. NORTH AMERICAN PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2021-2028 ($ MILLION)
  • 12. NORTH AMERICAN PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY END USER, 2021-2028 ($ MILLION)
  • 13. EUROPEAN PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 14. EUROPEAN PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2021-2028 ($ MILLION)
  • 15. EUROPEAN PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY END USER, 2021-2028 ($ MILLION)
  • 16. ASIA-PACIFIC PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 17. ASIA-PACIFIC PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2021-2028 ($ MILLION)
  • 18. ASIA-PACIFIC PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY END USER, 2021-2028 ($ MILLION)
  • 19. REST OF THE WORLD PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 20. REST OF THE WORLD PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2021-2028 ($ MILLION)
  • 21. REST OF THE WORLD PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY END USER, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL PRAVASTATIN MARKET, 2021-2028 ($ MILLION)
  • 2. GLOBAL PRAVASTATIN MARKET SHARE BY DOSAGE TYPE, 2021 VS 2028 (%)
  • 3. GLOBAL 10 MG PRAVASTATIN TABLETS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 4. GLOBAL 20 MG PRAVASTATIN TABLETS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 5. GLOBAL 40 MG PRAVASTATIN TABLETS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 6. GLOBAL 80 MG PRAVASTATIN TABLETS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 7. GLOBAL PRAVASTATIN MARKET SHARE BY END USER, 2021 VS 2028 (%)
  • 8. GLOBAL PRAVASTATIN FOR CHILDREN MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 9. GLOBAL PRAVASTATIN OF ADULTS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 10. GLOBAL PRAVASTATIN MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 11. US PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 12. CANADA PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 13. UK PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 14. FRANCE PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 15. GERMANY PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. ITALY PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. SPAIN PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. REST OF EUROPE PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. INDIA PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. CHINA PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. JAPAN PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. REST OF ASIA-PACIFIC PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. REST OF THE WORLD PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)